Adaptive Biotechnologies Corp [ADPT] moved up 0.51: Why It’s Important

Adaptive Biotechnologies Corp [NASDAQ: ADPT] gained 0.51% or 0.02 points to close at $3.96 with a heavy trading volume of 5278910 shares. The company report on February 14, 2024 at 4:05 PM that Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results.

“2023 was a year of execution for MRD and strategic evolution for IM. The MRD business ended the year with 53% growth in clonoSEQ tests delivered and IM achieved key target and drug discovery milestones in cancer and autoimmune disorders,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “2024 is off to a strong start. As momentum continues to build in both MRD and IM, we look forward to maximizing the value of each of these distinct opportunities for our patients and shareholders.”.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The daily chart for ADPT points out that the company has recorded -36.33% loss over the past six months.

If we look at the average trading volume of 1.34M shares, ADPT reached to a volume of 5278910 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Adaptive Biotechnologies Corp [ADPT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADPT shares is $8.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADPT stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JP Morgan have made an estimate for Adaptive Biotechnologies Corp shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 05, 2023.

The Average True Range (ATR) for Adaptive Biotechnologies Corp is set at 0.32, with the Price to Sales ratio for ADPT stock in the period of the last 12 months amounting to 3.37. The Price to Book ratio for the last quarter was 1.86, with the Price to Cash per share for the same quarter was set at 2.39.

Trading performance analysis for ADPT stock

Adaptive Biotechnologies Corp [ADPT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.90. With this latest performance, ADPT shares dropped by -2.22% in over the last four-week period, additionally sinking by -36.33% over the last 6 months – not to mention a drop of -54.38% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADPT stock in for the last two-week period is set at 48.96, with the RSI for the last a single of trading hit 52.69, and the three-weeks RSI is set at 47.45 for Adaptive Biotechnologies Corp [ADPT]. The present Moving Average for the last 50 days of trading for this stock 4.38, while it was recorded at 3.84 for the last single week of trading, and 5.67 for the last 200 days.

Adaptive Biotechnologies Corp [ADPT]: A deeper dive into fundamental analysis

Adaptive Biotechnologies Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.50 and a Current Ratio set at 4.66.

Adaptive Biotechnologies Corp [ADPT]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Adaptive Biotechnologies Corp posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -5.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADPT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptive Biotechnologies Corp go to 21.60%.

An analysis of Institutional ownership at Adaptive Biotechnologies Corp [ADPT]

The top three institutional holders of ADPT stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ADPT stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ADPT stock with ownership which is approximately 5.8325%.